BUND FINANCE › Stocks › NVO
Novo Nordisk A/S (NVO)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -2.32% below its 50-day average.
- It is -9.50% below its 200-day average (long-term downtrend).
- It sits at 13% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | DKK 140.8B | DKK 177.0B | DKK 232.3B | DKK 290.4B | DKK 309.1B |
| Net income | DKK 47.8B | DKK 55.5B | DKK 83.7B | DKK 101.0B | DKK 102.4B |
| EPS (diluted) | 10.37 | 12.22 | 18.62 | 22.63 | 23.03 |
| Gross margin | 83.2% | 83.9% | 84.6% | 84.7% | 81.0% |
| Operating margin | 41.7% | 42.3% | 44.2% | 44.2% | 41.3% |
| Net margin | 33.9% | 31.4% | 36.0% | 34.8% | 33.1% |
| Free cash flow | DKK 47.6B | DKK 64.1B | DKK 70.0B | DKK 69.7B | DKK 29.0B |
| Total debt | DKK 26.6B | DKK 25.8B | DKK 27.0B | DKK 102.8B | DKK 131.0B |
| Cash | DKK 10.7B | DKK 12.7B | DKK 14.4B | DKK 15.7B | DKK 26.5B |
Compound annual growth: revenue 21.7% · net income 21.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 30.5x | 26.4x |
| EV / EBITDA | — | 22.1x | 16.3x |
| Operating margin | 42.4% | — | 3.6% |
| Net margin | 33.9% | — | -0.0% |
| Debt / equity | 1.75 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.
About Novo Nordisk A/S
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice